| Literature DB >> 26498130 |
Emilie Le Rhun1,2,3, Marc C Chamberlain4, Fahed Zairi3,5, Christine Delmaire6, Ahmed Idbaih7,8, Florence Renaud9,10,11, Claude Alain Maurage9,10,11, Valérie Grégoire9,10,11.
Abstract
Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, anaplastic lymphoma kinase (ALK) expression and c-MET protein overexpression was observed. Conversely, no response to crizotinib was obtained in the second case with MET protein overexpression and c-MET amplification but no ALK expression or ALK gene amplification. These case studies suggest that novel targeted ALK inhibitors may provide relevant clinical benefit in selected cases in which driver mutations are demonstrable.Entities:
Keywords: ALK; MET; MET amplification; crizotinib; glioblastoma; targeted therapy
Mesh：
Substances：
Year: 2015 PMID： 26498130 PMCID： PMC6083940 DOI： 10.2217/cns.15.30
Source DB: PubMed Journal: CNS Oncol ISSN： 2045-0907